Next Article in Journal
Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset
Previous Article in Journal
Hcp Proteins of the Type VI Secretion System Promote Avian Pathogenic E. coli DE205B (O2:K1) to Induce Meningitis in Rats
Previous Article in Special Issue
Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial
 
 
Correction to Life 2022, 12(3), 453.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Coppock et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453

1
Division of Infectious Diseases, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Chestnut Street, Philadelphia, PA 19107, USA
2
Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
3
Jefferson Clinical Research Institute, Thomas Jefferson University, 833 Chestnut Street, Philadelphia, PA 19107, USA
4
Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
5
Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Chestnut Street, Philadelphia, PA 19107, USA
6
Department of Integrative Medicine and Nutritional Sciences, Sidney Kimmel Medical College, Thomas Jefferson University, 925 Chestnut Street, Philadelphia, PA 19107, USA
*
Authors to whom correspondence should be addressed.
Life 2022, 12(9), 1354; https://doi.org/10.3390/life12091354
Submission received: 13 April 2022 / Accepted: 17 May 2022 / Published: 31 August 2022
(This article belongs to the Special Issue Antimicrobial Mechanisms of Vitamin C)

Deletion of an Author

The authors wish to make a change to the author names (deleting one author—Constantine Daskalakis) for this paper [1]. Daskalakis has requested to be removed from the article. The correct authorship is as below:
Dagan Coppock 1,*, Pierre-Christian Violet 2, Gustavo Vasquez 1, Katherine Belden 1, Michael Foster 3, Bret Mullin 3, Devon Magee 3, Isabelle Mikell 4, Lokesh Shah 4, Victoria Powers 4, Brian Curcio 5, Daniel Monti 6 and Mark Levine 2,*
The “Author Contributions” statement thus should be updated to the following version:
  • Author Contributions: P.-C.V., D.M. (Daniel Monti) and M.L. conceived the study; D.C., D.M. (Daniel Monti), M.L. and M.F. developed the trial methodology; D.C., G.V., K.B. and B.M. reviewed and enrolled subjects; D.C., D.M. (Daniel Monti), G.V. and K.B. provided clinical oversight and monitored safety; B.M., D.M. (Devon Magee), I.M., L.S. and V.P. were responsible for preparing and curating data; B.C. and D.C. performed formal analyses; D.C. and M.L. prepared the original manuscript draft; all authors reviewed and edited the manuscript; D.M. (Daniel Monti) acquired funding; D.C., D.M. (Daniel Monti) and M.L. supervised overall efforts. All authors have read and agreed to the published version of the manuscript.

Text Correction

The second correction was the inclusion of the words “study-related” to the sentence: “There were no reported deaths in either arm.” This sentence has been changed to now read: “There were no reported study-related deaths in either arm.”
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Coppock, D.; Violet, P.-C.; Vasquez, G.; Belden, K.; Foster, M.; Mullin, B.; Magee, D.; Mikell, I.; Shah, L.; Powers, V.; et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Coppock, D.; Violet, P.-C.; Vasquez, G.; Belden, K.; Foster, M.; Mullin, B.; Magee, D.; Mikell, I.; Shah, L.; Powers, V.; et al. Correction: Coppock et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453. Life 2022, 12, 1354. https://doi.org/10.3390/life12091354

AMA Style

Coppock D, Violet P-C, Vasquez G, Belden K, Foster M, Mullin B, Magee D, Mikell I, Shah L, Powers V, et al. Correction: Coppock et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453. Life. 2022; 12(9):1354. https://doi.org/10.3390/life12091354

Chicago/Turabian Style

Coppock, Dagan, Pierre-Christian Violet, Gustavo Vasquez, Katherine Belden, Michael Foster, Bret Mullin, Devon Magee, Isabelle Mikell, Lokesh Shah, Victoria Powers, and et al. 2022. "Correction: Coppock et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453" Life 12, no. 9: 1354. https://doi.org/10.3390/life12091354

APA Style

Coppock, D., Violet, P. -C., Vasquez, G., Belden, K., Foster, M., Mullin, B., Magee, D., Mikell, I., Shah, L., Powers, V., Curcio, B., Monti, D., & Levine, M. (2022). Correction: Coppock et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453. Life, 12(9), 1354. https://doi.org/10.3390/life12091354

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop